This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.

γδ2 T cells

Eliciting a Robust Anticancer Immune Response
Acepodia’s γδ2 T cells program harnesses the unique properties of γδ2 T cells to develop a new class of off-the-shelf cell therapies for the treatment of cancer. γδ2 T cells have characteristics of both the innate and adaptive immune systems that make them an ideal chassis for the development of cell therapies. This cell type can directly recognize and attack cancerous cells as well as coordinate a broad antitumor immune response by recruiting and activating other immune factors and cells to the site of disease. γδ2 T cells have also been shown to preferentially traffic to distinct tissues and could be ideally suited for more targeted treatment of certain types of cancers.
A Unique, Powerful Cancer-Fighting Cell
Advantages of Acepodia’s γδ2 T Cell Technology

Advantages of Acepodia’s γδ2 T Cell Technology

Acepodia has developed a unique γδ2 T cells that are enriched to provide the added benefits of NK functions through its proprietary selection and expansion technology. The γδ2 T cells express high level of activating receptors such as CD2 and NKG2D and low level of inhibitory receptors, enhancing potency to directly kill the tumor cells and indirectly activate other immune factors against the malignancy. Unlike traditional T cell therapies, γδ2 T cells can be administered off-the-shelf and do not need to be tailored for each individual patient, allowing for a streamlined manufacturing process and broader potential use. While an attractive candidate for cell therapies, gamma delta2 T cells only represent a small fraction of circulating T cells which has greatly limited their use in the past.
Evaluating the Promise of γδ2 T Cells

Evaluating the Promise of γδ2 T Cells

Acepodia is overcoming the limited nature of γδ2 T cells by developing a proprietary allogeneic γδ2 T cell production that represents a consistent and scalable source of γδ2 T cells. Using its integrated approach, Acepodia is enhancing its γδ2 T cells for the development of therapies that can complement its other cell therapy programs.
Manufacturing & Off-the-shelf Scalability

Manufacturing & Off-the-shelf Scalability

Current autologous cell therapies that are generated from a patient’s own cells require weeks to prepare. Unlike most αβT cells, γδ2 T cells can be given off-the-shelf, meaning that they do not need to be tailored to an individual patient which allows for a streamlined manufacturing process and increased scalability. Moreover, γδ2 T cells can be cryopreserved so that they are ready when patients need them. Cumulatively, these benefits translate to lower costs and greater availability for patients.
Increased Tolerability

Increased Tolerability

γδ2 T cell therapies may have a reduced risk for dangerous and potentially life-threatening reactions such as graft-versus-host disease (GvHD) or cytokine storm syndrome.

Guiding γδ2 T Cells Directly to Tumor Sites: ACC

Currently available cell therapies also present challenges in effectively engaging cancer cells due to immunosuppression caused by the tumor microenvironment. By uniting its potent γδ2 T cells with well-established, as well as proprietary and novel tumor-targeting mechanisms, Acepodia’s cell therapy candidates are designed to target cancer cells and overcome tumor defenses to deliver their potent, cancer-killing cellular payload.




Phase I
Phase II
CD20 Targeting, ACC-γδ2 T Cell Therapy
Phase I ​
EGFR Targeting, ACC-γδ2 T Cell Therapy
Preclinical ​
PD-L1 Targeting, ACC-γδ2 T Cell Therapy
Preclinical ​
We have collaborated with biopharmaceutical partners and academic institutes worldwide.